Medical Devices

New research proves pocket-sized, AI-powered ultrasound is a game-changer for urgent care, tackling staff shortages and improving patient outcomes.

A new deal for the rare isotope Actinium-225 could break a major supply bottleneck, accelerating the development of highly targeted cancer treatments.

South Korea's Hugel shatters sales records with a 105% surge in the Americas, signaling a major power shift in the global medical aesthetics market.

With a 135% revenue surge and a key FDA submission for its kidney transplant drug, Hansa Biopharma is poised for a pivotal year of expansion.

A wrongful death lawsuit alleges Abbott's FreeStyle Libre 3 sensor gave a fatal false reading, part of a massive recall affecting 3 million devices.

A new book offers a critical roadmap for medical device developers facing a storm of new AI regulations, complex FDA rules, and evolving IP law.

AI genomics firm partners with two major US health systems, aiming to accelerate cancer and rare disease diagnostics for 60,000 patients annually.

Promising clinical trial results show a new inhaler delivers nicotine as fast as a cigarette, offering a breakthrough for smoking cessation after decades of failure.

With 100+ new locations in 2025, Smile Doctors' rapid expansion signals a major shift. What does this mean for independent doctors and patient care?

Bolstered by a top regulatory expert and unique veterinary data, Vivos Inc. is set to file for human trials of its precision injectable cancer treatment.

NEXGEL has financing for a major acquisition, but the deal hinges on a critical due diligence phase. What does this mean for the hydrogel innovator?

ARS Pharma's neffy challenges the EpiPen with new data on efficacy, cost-effectiveness, and patient preference, promising a less intimidating allergy emergency.

A new lawsuit claims private equity giant TPG hid implant defects and forced a bankruptcy, leaving thousands of injured patients to pay the price.

Following a landmark FDA approval, IceCure Medical's long-serving CFO is exiting, placing the company at a pivotal financial crossroads for its new treatment.

With its IPO complete, Cambridge Acquisition Corp. enters a disciplined SPAC market with a clear focus on wellness, hemp, and psychedelic tech targets.

Belgian biotech Agomab Therapeutics secures $200 million in its Nasdaq debut, fueling its mission to develop therapies for debilitating fibrotic conditions.

APhA awards honor the growing role of pharmacists in national immunization, highlighting innovation, dedication, and the future of community healthcare.

A new initiative highlights how wrongful death claims can offer financial relief to grieving families and address unpaid costs in the healthcare system.

A national report card gives the U.S. a 'B' on rare disease policy, but stark state-by-state disparities leave millions vulnerable to financial ruin.

With transplant patient needs growing, BioMatrix promotes Heidi Ulbrich to manage its services, highlighting a model built for speed and complex care.